Liranaftate cream in treatment of tinea cruris and tinea corporis:a muiticenter randomized double-blind vehicle-controlled clinical trial

AIM:To study and evaluate the efficacy and safety of 2% liranaftate cream in the topical treatment of tinea cruris and tinea corporis.METHODS:Clinical study was done on 144 patients with tinea cruris and tinea corporis for 4 weeks in a multiple-center randomized,double-blind,parallel trial.Patients were randomly divided into trial group (treated with 2% liranaftate cream) and control group (treated with 1% bifonazole cream);and creams were locally administered once daily in each group for 2 weeks.The clinical follow up was taken at 1st,2nd week since the beginning of treatment and 2 weeks after the treatment. RESULTS:One hundred and forty-two patients had completed the trials,with 70 in the control group and 72 in the trial group.The total cure rates were 68% in trial group,and 61% in control group.The total efficacy rate was 99% in trial group,and 90% in control group.The mycological cure rate was 99% and 96% in trial group and control group,respectively.No adverse effects occurred in both groups.There were no significant differences between the two groups involving clinical efficacy,mycological effectiveness,integrative efficiency and adverse effects (P0.05).CONCLUSION:2% topical liranaftate cream has the same good efficacy and safety profile as 1% bifonazole cream in the treatment of tinea cruris and tinea corporis.